Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Status:
RECRUITING
Trial end date:
2029-04-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.